EcoDrugPlus

Glycogen Synthase Kinase-3 Beta-Like

Ensembl ID : ENSOKIG00005000138
Gene Symbol: LOC109878893
3 Cross references
182 Possible Orthologues:

Glycogen Synthase Kinase-3 Beta-Like

Ensembl ID : ENSOKIG00005034799
Gene Symbol: LOC109877714
3 Cross references
182 Possible Orthologues:

Gonadotropin Releasing Hormone Receptor 1

Ensembl ID : ENSOKIG00005018676
Gene Symbol: GNRHR1
1 Cross references
129 Possible Orthologues:

Gonadotropin-Releasing Hormone Ii Receptor

Ensembl ID : ENSOKIG00005025815
Gene Symbol: LOC109903552
2 Cross references
129 Possible Orthologues:

Growth Hormone Secretagogue Receptor

Ensembl ID : ENSOKIG00005020526
Gene Symbol: GHSR
3 Cross references
208 Possible Orthologues:

Growth Hormone Secretagogue Receptor

Ensembl ID : ENSOKIG00005019119
Gene Symbol: GHSR
3 Cross references
207 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSOKIG00005027757
Gene Symbol: GUCY1A1
3 Cross references
195 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSOKIG00005008951
Gene Symbol: GUCY1A2
3 Cross references
196 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSOKIG00005014744
Gene Symbol: GUCY1A2
3 Cross references
197 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSOKIG00005036704
Gene Symbol: GUCY1B1
1 Cross references
204 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSOKIG00005027780
Gene Symbol: GUCY1B1
1 Cross references
202 Possible Orthologues:

Guanylate Cyclase Soluble Subunit Alpha-1-Like

Ensembl ID : ENSOKIG00005036689
Gene Symbol: LOC109893862
3 Cross references
195 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).